Summary

Ebola Virus Vaccine Market – Scope of Report
TMR’s report on the global Ebola virus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global Ebola virus vaccine market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Ebola virus vaccine market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Ebola virus vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Ebola virus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Ebola virus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Ebola virus vaccine market.

The report delves into the competitive landscape of the global Ebola virus vaccine market. Key players operating in the global Ebola virus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Ebola virus vaccine market profiled in this report.

Key Questions Answered in Global Ebola virus vaccine Market Report
• What is the sales/revenue generated by Ebola virus vaccine across all regions during the forecast period?
• What are the opportunities in the global Ebola virus vaccine market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Ebola Virus Vaccine Market – Research Objectives and Research Approach
The comprehensive report on the global Ebola virus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Ebola virus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Ebola virus vaccine market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ebola Virus Vaccine Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Ebola Virus Vaccine Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Ebola Virus Vaccine Market Analysis and Forecast, by Vaccine Type
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Vaccine Type, 2020-2034
        6.3.1. cAd3-ZEBOV
        6.3.2. rVSV-ZEBOV
    6.4. Market Attractiveness, by Vaccine Type
7. Global Ebola Virus Vaccine Market Analysis and Forecast, by Route of Administration
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Route of Administration, 2020-2034
        7.3.1. Oral
        7.3.2. Intravenous
    7.4. Market Attractiveness, by Route of Administration
8. Global Ebola Virus Vaccine Market Analysis and Forecast, By Strain Type
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, By Strain Type, 2020-2034
        8.3.1. Zaire
        8.3.2. Sudan
        8.3.3. Tai Forest
        8.3.4. Reston
        8.3.5. Bundibugyo Virus
    8.4. Market Attractiveness, By Strain Type
9. Global Ebola Virus Vaccine Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Distribution Channel, 2020-2034
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness, by Distribution Channel
10. Global Ebola Virus Vaccine Market Analysis and Forecast, by End-user
    10.1. Introduction and Definitions
    10.2. Key Findings/Developments
    10.3. Market Value Forecast, by End-user, 2020-2034
        10.3.1. Hospitals
        10.3.2. Homecare
        10.3.3. Specialty Clinics
        10.3.4. Ambulatory Surgical Centers
        10.3.5. Others (Outpatient Facilities, etc.)
    10.4. Market Attractiveness, by End-user
11. Global Ebola Virus Vaccine Market Analysis and Forecast, by Region
    11.1. Key Findings
    11.2. Market Value Forecast, by Region, 2020-2034
        11.2.1. North America
        11.2.2. Europe
        11.2.3. Asia Pacific
        11.2.4. Latin America
        11.2.5. Middle East & Africa
    11.3. Market Attractiveness, by Region
12. North America Ebola Virus Vaccine Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Vaccine Type, 2020-2034
        12.2.1. CAd3-ZEBOV
        12.2.2. RVSV-ZEBOV
    12.3. Market Attractiveness, by Vaccine Type
    12.4. Market Value Forecast, by Route of Administration, 2020-2034
        12.4.1. Oral
        12.4.2. Intravenous
    12.5. Market Attractiveness, by Route of Administration
    12.6. Market Value Forecast, By Strain Type, 2020-2034
        12.6.1. Zaire
        12.6.2. Sudan
        12.6.3. Tai Forest
        12.6.4. Reston
        12.6.5. Bundibugyo Virus
    12.7. Market Attractiveness, By Strain Type
    12.8. Market Value Forecast, by Distribution Channel, 2020-2034
        12.8.1. Hospital Pharmacies
        12.8.2. Retail Pharmacies
        12.8.3. Online Pharmacies
    12.9. Market Attractiveness, by Distribution Channel
    12.10. Market Value Forecast, by End-user, 2020-2034
        12.10.1. Hospitals
        12.10.2. Homecare
        12.10.3. Specialty Clinics
        12.10.4. Ambulatory Surgical Centers
        12.10.5. Others (Outpatient Facilities, etc.)
    12.11. Market Attractiveness, by End-user
    12.12. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.12.1. U.S.
        12.12.2. Canada
    12.13. Market Attractiveness Analysis
        12.13.1. By Vaccine Type
        12.13.2. By Route of Administration
        12.13.3. By Strain Type
        12.13.4. By Distribution Channel
        12.13.5. By End-user
        12.13.6. By Country
13. Europe Ebola Virus Vaccine Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Vaccine Type, 2020-2034
        13.2.1. CAd3-ZEBOV
        13.2.2. RVSV-ZEBOV
    13.3. Market Attractiveness, by Vaccine Type
    13.4. Market Value Forecast, by Route of Administration, 2020-2034
        13.4.1. Oral
        13.4.2. Intravenous
    13.5. Market Attractiveness, by Route of Administration
    13.6. Market Value Forecast, By Strain Type, 2020-2034
        13.6.1. Zaire
        13.6.2. Sudan
        13.6.3. Tai Forest
        13.6.4. Reston
        13.6.5. Bundibugyo Virus
    13.7. Market Attractiveness, By Strain Type
    13.8. Market Value Forecast, by Distribution Channel, 2020-2034
        13.8.1. Hospital Pharmacies
        13.8.2. Retail Pharmacies
        13.8.3. Online Pharmacies
    13.9. Market Attractiveness, by Distribution Channel
    13.10. Market Value Forecast, by End-user, 2020-2034
        13.10.1. Hospitals
        13.10.2. Homecare
        13.10.3. Specialty Clinics
        13.10.4. Ambulatory Surgical Centers
        13.10.5. Others (Outpatient Facilities, etc.)
    13.11. Market Attractiveness, by End-user
    13.12. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.12.1. Germany
        13.12.2. U.K.
        13.12.3. France
        13.12.4. Italy
        13.12.5. Spain
        13.12.6. Rest of Europe
    13.13. Market Attractiveness Analysis
        13.13.1. By Vaccine Type
        13.13.2. By Route of Administration
        13.13.3. By Strain Type
        13.13.4. By Distribution Channel
        13.13.5. By End-user
        13.13.6. By Country/Sub-region
14. Asia Pacific Ebola Virus Vaccine Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Vaccine Type, 2020-2034
        14.2.1. CAd3-ZEBOV
        14.2.2. RVSV-ZEBOV
    14.3. Market Attractiveness, by Vaccine Type
    14.4. Market Value Forecast, by Route of Administration, 2020-2034
        14.4.1. Oral
        14.4.2. Intravenous
    14.5. Market Attractiveness, by Route of Administration
    14.6. Market Value Forecast, By Strain Type, 2020-2034
        14.6.1. Zaire
        14.6.2. Sudan
        14.6.3. Tai Forest
        14.6.4. Reston
        14.6.5. Bundibugyo Virus
    14.7. Market Attractiveness, By Strain Type
    14.8. Market Value Forecast, by Distribution Channel, 2020-2034
        14.8.1. Hospital Pharmacies
        14.8.2. Retail Pharmacies
        14.8.3. Online Pharmacies
    14.9. Market Attractiveness, by Distribution Channel
    14.10. Market Value Forecast, by End-user, 2020-2034
        14.10.1. Hospitals
        14.10.2. Homecare
        14.10.3. Specialty Clinics
        14.10.4. Ambulatory Surgical Centers
        14.10.5. Others (Outpatient Facilities, etc.)
    14.11. Market Attractiveness, by End-user
    14.12. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.12.1. China
        14.12.2. Japan
        14.12.3. India
        14.12.4. Australia & New Zealand
        14.12.5. Rest of Asia Pacific
    14.13. Market Attractiveness Analysis
        14.13.1. By Vaccine Type
        14.13.2. By Route of Administration
        14.13.3. By Strain Type
        14.13.4. By Distribution Channel
        14.13.5. By End-user
        14.13.6. By Country/Sub-region
15. Latin America Ebola Virus Vaccine Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Vaccine Type, 2020-2034
        15.2.1. CAd3-ZEBOV
        15.2.2. RVSV-ZEBOV
    15.3. Market Attractiveness, by Vaccine Type
    15.4. Market Value Forecast, by Route of Administration, 2020-2034
        15.4.1. Oral
        15.4.2. Intravenous
    15.5. Market Attractiveness, by Route of Administration
    15.6. Market Value Forecast, By Strain Type, 2020-2034
        15.6.1. Zaire
        15.6.2. Sudan
        15.6.3. Tai Forest
        15.6.4. Reston
        15.6.5. Bundibugyo Virus
    15.7. Market Attractiveness, By Strain Type
    15.8. Market Value Forecast, by Distribution Channel, 2020-2034
        15.8.1. Hospital Pharmacies
        15.8.2. Retail Pharmacies
        15.8.3. Online Pharmacies
    15.9. Market Attractiveness, by Distribution Channel
    15.10. Market Value Forecast, by End-user, 2020-2034
        15.10.1. Hospitals
        15.10.2. Homecare
        15.10.3. Specialty Clinics
        15.10.4. Ambulatory Surgical Centers
        15.10.5. Others (Outpatient Facilities, etc.)
    15.11. Market Attractiveness, by End-user
    15.12. Market Value Forecast, by Country/Sub-region, 2020-2034
        15.12.1. Brazil
        15.12.2. Mexico
        15.12.3. Rest of Latin America
    15.13. Market Attractiveness Analysis
        15.13.1. By Vaccine Type
        15.13.2. By Route of Administration
        15.13.3. By Strain Type
        15.13.4. By Distribution Channel
        15.13.5. By End-user
        15.13.6. By Country/Sub-region
16. Middle East & Africa Ebola Virus Vaccine Market Analysis and Forecast
    16.1. Introduction
        16.1.1. Key Findings
    16.2. Market Value Forecast, by Vaccine Type, 2020-2034
        16.2.1. CAd3-ZEBOV
        16.2.2. RVSV-ZEBOV
    16.3. Market Attractiveness, by Vaccine Type
    16.4. Market Value Forecast, by Route of Administration, 2020-2034
        16.4.1. Oral
        16.4.2. Intravenous
    16.5. Market Attractiveness, by Route of Administration
    16.6. Market Value Forecast, By Strain Type, 2020-2034
        16.6.1. Zaire
        16.6.2. Sudan
        16.6.3. Tai Forest
        16.6.4. Reston
        16.6.5. Bundibugyo Virus
    16.7. Market Attractiveness, By Strain Type
    16.8. Market Value Forecast, by Distribution Channel, 2020-2034
        16.8.1. Hospital Pharmacies
        16.8.2. Retail Pharmacies
        16.8.3. Online Pharmacies
    16.9. Market Attractiveness, by Distribution Channel
    16.10. Market Value Forecast, by End-user, 2020-2034
        16.10.1. Hospitals
        16.10.2. Homecare
        16.10.3. Specialty Clinics
        16.10.4. Ambulatory Surgical Centers
        16.10.5. Others (Outpatient Facilities, etc.)
    16.11. Market Attractiveness, by End-user
    16.12. Market Value Forecast, by Country/Sub-region, 2020-2034
        16.12.1. GCC Countries
        16.12.2. South Africa
        16.12.3. Rest of Middle East & Africa
    16.13. Market Attractiveness Analysis
        16.13.1. By Vaccine Type
        16.13.2. By Route of Administration
        16.13.3. By Strain Type
        16.13.4. By Distribution Channel
        16.13.5. By End-user
        16.13.6. By Country/Sub-region
17. Competition Landscape
    17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    17.2. Market Share Analysis, by Company (2023)
    17.3. Company Profiles
        17.3.1. Arbutus Biopharma Corporation
            17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.1.2. Product Portfolio
            17.3.1.3. Financial Overview
            17.3.1.4. SWOT Analysis
            17.3.1.5. Strategic Overview
        17.3.2. GSK plc
            17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.2.2. Product Portfolio
            17.3.2.3. Financial Overview
            17.3.2.4. SWOT Analysis
            17.3.2.5. Strategic Overview
        17.3.3. Johnson & Johnson Services, Inc.
            17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.3.2. Product Portfolio
            17.3.3.3. Financial Overview
            17.3.3.4. SWOT Analysis
            17.3.3.5. Strategic Overview
        17.3.4. AIM ImmunoTech Inc.
            17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.4.2. Product Portfolio
            17.3.4.3. Financial Overview
            17.3.4.4. SWOT Analysis
            17.3.4.5. Strategic Overview
        17.3.5. BioCryst Pharmaceuticals
            17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.5.2. Product Portfolio
            17.3.5.3. Financial Overview
            17.3.5.4. SWOT Analysis
            17.3.5.5. Strategic Overview
        17.3.6. NanoViricides, Inc.
            17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.6.2. Product Portfolio
            17.3.6.3. Financial Overview
            17.3.6.4. SWOT Analysis
            17.3.6.5. Strategic Overview
        17.3.7. NewLink Genetics Corporation
            17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.7.2. Product Portfolio
            17.3.7.3. Financial Overview
            17.3.7.4. SWOT Analysis
            17.3.7.5. Strategic Overview
        17.3.8. Chimerix, Inc.
            17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.8.2. Product Portfolio
            17.3.8.3. Financial Overview
            17.3.8.4. SWOT Analysis
            17.3.8.5. Strategic Overview
        17.3.9. Sarepta Therapeutics, Inc.
            17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.9.2. Product Portfolio
            17.3.9.3. Financial Overview
            17.3.9.4. SWOT Analysis
            17.3.9.5. Strategic Overview
        17.3.10. Mapp Biopharmaceutical, Inc.
            17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.10.2. Product Portfolio
            17.3.10.3. Financial Overview
            17.3.10.4. SWOT Analysis
            17.3.10.5. Strategic Overview